<DOC>
	<DOCNO>NCT01068873</DOCNO>
	<brief_summary>The primary objective pilot study assess efficacy lopinavir/ritonavir ( Kaletra , protease inhibitor , PI ) use combination maraviroc ( Selzentry , HIV entry inhibitor ) treatment antiretroviral naïve HIV infect patient . Twenty patient enrol studied 48 week .</brief_summary>
	<brief_title>Kaletra Maraviroc Antiretroviral Therapy ( ART ) -Naive Patients ( KALMAR Study )</brief_title>
	<detailed_description>As patient HIV living longer important explore antiretroviral treatment may reduce development long term complication preserve future HIV treatment option . This trial explore antiretroviral treatment regimen include nucleoside reverse transcriptase inhibitor class think long-term toxicity . This non-randomized , open label trial participant meeting entry requirement . Participants evaluate screening , baseline , week 4 , 8 , 12 , 24 , 36 , 48 include clinical assessment well laboratory assessment . An interim analysis perform patient reach week 24 visit .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>The patient sign date approve informed consent form . There confirmed laboratory diagnosis HIV infection ( positive ELISA HIV antibody test confirm Western blot , p24 antigen assay , quantitative HIV1 RNA assay , HIV culture ) . The patient least 18 year age . ARTnaïve , lopinavir/ritonavir susceptible genotypic testing , CCR5tropic virus Trofile testing ( ESTA ) . Negative pregnancy test within 72 hour prior start study woman childbearing potential . Females childbearing potential male must utilize effective barrier contraception . HIV RNA great 1,000 copy per mL entry . Liver enzymes ( AST , ALT ) &lt; 3 time upper limit normal . Patients pregnant breastfeeding . Active alcohol substance abuse sufficient , Investigator 's opinion make compliance study protocol unlikely . Suspected active HIVrelated opportunistic infection condition require acute therapy within 30 day entry trial . Patients therapy hepatitis B . Patients hepatitis B surface antigen , evidence active hepatitis B positive hepatitis B DNA and/or presence hepatitis e antigen e antibody . Acute hepatitis B C within 60 day entry . Patients harbor preexistent coreceptor CXCR4 tropic dualor mixedtropic HIV . Patients harbor HIV resistant lopinavir/ritonavir genotypic test . The presence decompensated heart failure , myocardial infarction within 1 year , bypass surgery , severe vascular disease , active hepatobiliary disease . Concomitant use rifampin , ergot derivative ( i.e . dihydroergotamine , ergotamine ) , cisapride , lovastatin , simvastatin , triazolam , orally administer midazolam , carbamazepine , phenytoin , St. John 's wort , ketoconazole , itraconazole , clarithromycin , telithromycin , amiodarone , bepridil , flecainide , propafenone , quinidine , voriconazole nefazodone . Patients concomitant diagnosis malignancy cancer basal cell carcinoma within past 5 year . Concomitant use investigational agent include use investigational vaccine . Any clinical condition prior therapy , opinion investigator , would make patient unsuitable study , unable comply dose requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>HIV</keyword>
	<keyword>Protease Inhibitor</keyword>
	<keyword>CCR5 Co-receptor Antagonist</keyword>
	<keyword>treatment naive</keyword>
</DOC>